ERBB2 and breast carcinoma: In breast cancer, patient stratification based on expression of tumour markers (e.g., ER, PR and HER2 in breast cancer) has guided treatment strategies for over 30 years (Cardoso et al., 2016) laying the foundation for remarkable advances in molecular diagnostics (Buus et al., 2021).